AU5886296A
(en)
|
1995-06-02 |
1996-12-18 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
|
US5908858A
(en)
|
1996-04-05 |
1999-06-01 |
Sankyo Company, Limited |
1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
|
GEP20032998B
(en)
*
|
1996-04-12 |
2003-06-25 |
Searle & Co |
Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
|
US6586458B1
(en)
|
1996-08-16 |
2003-07-01 |
Pozen Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US8022095B2
(en)
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
EP0971714B1
(en)
*
|
1997-04-03 |
2002-10-09 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
|
US20040072889A1
(en)
*
|
1997-04-21 |
2004-04-15 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
|
RS49982B
(sr)
|
1997-09-17 |
2008-09-29 |
Euro-Celtique S.A., |
Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
|
NZ333399A
(en)
|
1997-12-24 |
2000-05-26 |
Sankyo Co |
Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
|
EP1061908A4
(en)
*
|
1998-03-13 |
2007-01-24 |
Merck & Co Inc |
COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY MIXING SYNDROME AND ASSOCIATED CONDITIONS
|
US6136804A
(en)
*
|
1998-03-13 |
2000-10-24 |
Merck & Co., Inc. |
Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
|
AU4428899A
(en)
|
1998-06-08 |
1999-12-30 |
Advanced Medicine, Inc. |
Multibinding inhibitors of cyclooxygenase-2
|
AR024222A1
(es)
*
|
1998-10-16 |
2002-09-25 |
Palau Pharma Sa |
Imidazoles con actividad antiinflamatoria un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen
|
EP1126841B1
(en)
*
|
1998-11-02 |
2004-12-15 |
Merck & Co., Inc. |
Combinations of a 5ht1b/1d agonist and a selective cox-2 inhibitor for the treatment of migraine
|
AU1398899A
(en)
*
|
1998-11-12 |
2000-06-05 |
Algos Pharmaceutical Corporation |
Cox-2 inhibitors in combination with centrally acting analgesics
|
US6649645B1
(en)
*
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
US20030119895A1
(en)
*
|
1998-12-23 |
2003-06-26 |
Pharmacia Corporation |
Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
WO2000048583A2
(en)
*
|
1999-02-19 |
2000-08-24 |
Pozen Inc. |
Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
|
US20010024664A1
(en)
*
|
1999-03-19 |
2001-09-27 |
Obukowicz Mark G. |
Selective COX-2 inhibition from edible plant extracts
|
WO2001028548A1
(en)
*
|
1999-10-19 |
2001-04-26 |
Texas Heart Institute |
Treatment of heart disease with cox-2 inhibitors
|
AU784490B2
(en)
*
|
1999-12-08 |
2006-04-13 |
Pharmacia Corporation |
Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
|
EP1239857B1
(en)
*
|
1999-12-22 |
2006-04-19 |
Pharmacia Corporation |
Dual-release compositions of a cyclooxygenase-2- inhibitor
|
IL150368A0
(en)
|
1999-12-23 |
2002-12-01 |
Nitromed Inc |
Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
|
CN100357244C
(zh)
|
2000-02-16 |
2007-12-26 |
布里格姆及妇女医院股份有限公司 |
阿司匹林触发的脂质介体
|
EP1259504A1
(en)
*
|
2000-03-03 |
2002-11-27 |
Pfizer Products Inc. |
Pyrazole ether derivatives as anti-inflammatory/analgesic agents
|
US20070072861A1
(en)
*
|
2000-03-27 |
2007-03-29 |
Barbara Roniker |
Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
|
ES2166710B1
(es)
*
|
2000-04-25 |
2004-10-16 |
J. URIACH & CIA, S.A. |
Nuevos compuestos heterociclicos con actividad antiinflamatoria.
|
EP1296971A2
(en)
*
|
2000-04-25 |
2003-04-02 |
Pharmacia Corporation |
2-fluorobenzenesulfonyl compounds for the treatment of inflammation
|
WO2002005848A2
(en)
*
|
2000-07-13 |
2002-01-24 |
Pharmacia Corporation |
Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
|
DK1303265T3
(da)
|
2000-07-20 |
2007-11-12 |
Lauras As |
Anvendelse af COX-2-inhibitorer, som immunostimulerende midler ved behandling af HIV eller AIDS
|
US20030219461A1
(en)
*
|
2000-09-12 |
2003-11-27 |
Britten Nancy J. |
Parenteral combination therapy for infective conditions
|
US20050004199A1
(en)
*
|
2000-09-18 |
2005-01-06 |
George Hartman |
Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
|
WO2002030358A2
(en)
*
|
2000-10-11 |
2002-04-18 |
Tularik Inc. |
Modulation of ccr4 function
|
JP2004529079A
(ja)
*
|
2000-12-15 |
2004-09-24 |
ファルマシア・コーポレーション |
植物抽出物による選択的cox−2阻害
|
JP2004517838A
(ja)
*
|
2000-12-15 |
2004-06-17 |
ファルマシア・コーポレーション |
非食用植物抽出物による選択的cox−2阻害
|
AU2002249812B2
(en)
|
2000-12-21 |
2005-11-10 |
Nicox S.A. |
Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
JP2004522754A
(ja)
*
|
2001-02-02 |
2004-07-29 |
ファルマシア・コーポレーション |
月経困難症の治療および予防のための組み合わせ治療としてシクロオキシゲナーゼ‐2阻害剤および性ステロイドを使用する方法
|
AU2002306868A1
(en)
*
|
2001-03-28 |
2002-10-15 |
Pharmacia Corporation |
Therapeutic combinations for cardiovascular and inflammatory indications
|
PE20021017A1
(es)
*
|
2001-04-03 |
2002-11-24 |
Pharmacia Corp |
Composicion parenteral reconstituible
|
ITMI20010733A1
(it)
|
2001-04-05 |
2002-10-05 |
Recordati Chem Pharm |
Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
|
US20030105144A1
(en)
*
|
2001-04-17 |
2003-06-05 |
Ping Gao |
Stabilized oral pharmaceutical composition
|
US6673818B2
(en)
*
|
2001-04-20 |
2004-01-06 |
Pharmacia Corporation |
Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
|
WO2002094264A1
(en)
*
|
2001-05-23 |
2002-11-28 |
Tularik Inc. |
Ccr4 antagonists
|
US20030153801A1
(en)
*
|
2001-05-29 |
2003-08-14 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
|
BR0210104A
(pt)
*
|
2001-05-31 |
2004-06-08 |
Pharmacia Corp |
Composição inibidora seletiva de ciclooxigenase-2 permeável à pele
|
US20060167074A1
(en)
*
|
2001-06-19 |
2006-07-27 |
Norbert Muller |
Methods and compositions for the treatment of psychiatric disorders
|
DE10129320A1
(de)
*
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
US20040067992A1
(en)
*
|
2001-08-10 |
2004-04-08 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
|
MXPA04001268A
(es)
*
|
2001-08-10 |
2004-05-27 |
Pharmacia Corp |
Inhibidor de anhidrasa carbonica.
|
US20050101563A1
(en)
*
|
2001-08-14 |
2005-05-12 |
Pharmacia Corporation |
Method and compositions for the treatment and prevention of pain and inflammation
|
US20030114416A1
(en)
*
|
2001-08-14 |
2003-06-19 |
Pharmacia Corporation |
Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
JP2005506982A
(ja)
*
|
2001-09-10 |
2005-03-10 |
スージェン・インコーポレーテッド |
キナーゼ阻害剤としての3−(4,5,6,7−テトラヒドロインドール−2−イルメチリデン)−2−インドリノン誘導体
|
US20030114483A1
(en)
*
|
2001-09-18 |
2003-06-19 |
Pharmacia Corporation |
Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
US20030236308A1
(en)
*
|
2001-09-18 |
2003-12-25 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
AU2002330042A1
(en)
|
2001-09-18 |
2003-04-01 |
Onconova Therapeutics, Inc. |
Process for the preparation of 1,5-diarylpyrazoles
|
WO2003024958A2
(en)
*
|
2001-09-18 |
2003-03-27 |
Onconova Therapeutics, Inc. |
Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
|
DE60220422T2
(de)
*
|
2001-09-19 |
2008-02-07 |
Pharmacia Corp. |
Substituierte pyrazol-verbindungen zur behandlung von entzündungen
|
MXPA04003072A
(es)
*
|
2001-10-02 |
2004-09-06 |
Pharmacia Corp |
Procedimiento para preparar compuestos de bencenosulfonilo.
|
AR037097A1
(es)
|
2001-10-05 |
2004-10-20 |
Novartis Ag |
Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
|
EP1578721A2
(en)
*
|
2001-10-12 |
2005-09-28 |
Onconova Therapeutics, Inc. |
Processes for the preparation of substituted isoxazoles and 2-isoxazolines
|
US20030162824A1
(en)
*
|
2001-11-12 |
2003-08-28 |
Krul Elaine S. |
Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
|
CN1615135A
(zh)
*
|
2001-11-13 |
2005-05-11 |
法马西亚公司 |
磺酰胺前药如帕瑞考昔的口服剂型
|
DE60231439D1
(de)
|
2001-12-06 |
2009-04-16 |
Merck & Co Inc |
Mitotische kinesinhemmer
|
US20040062823A1
(en)
*
|
2001-12-13 |
2004-04-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from non-edible plant extracts
|
US20040126438A1
(en)
*
|
2001-12-13 |
2004-07-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from plant extracts
|
AU2002353147A1
(en)
*
|
2001-12-13 |
2003-06-30 |
Abbott Laboratories |
3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
|
RU2004121147A
(ru)
*
|
2002-01-10 |
2005-04-10 |
Фармация Энд Апджон Компани (Us) |
Применение ингибиторов сох-2 в сочетании с противовирусными агентами для лечения инфекции вируса папилломы
|
US20030212138A1
(en)
*
|
2002-01-14 |
2003-11-13 |
Pharmacia Corporation |
Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
TW200403072A
(en)
*
|
2002-01-23 |
2004-03-01 |
Upjohn Co |
Combination therapy for the treatment of bacterial infections
|
WO2004026235A2
(en)
*
|
2002-09-20 |
2004-04-01 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical compositions with improved dissolution
|
US7927613B2
(en)
*
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
US7790905B2
(en)
*
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
US20100311701A1
(en)
*
|
2002-02-15 |
2010-12-09 |
Transform Pharmaceuticals, Inc |
Pharmaceutical Co-Crystal Compositions
|
EP1915992A1
(en)
|
2002-02-19 |
2008-04-30 |
Pharmacia Corporation |
Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
|
CA2477923C
(en)
*
|
2002-03-01 |
2021-02-23 |
University Of South Florida |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
EP1485362A1
(en)
*
|
2002-03-15 |
2004-12-15 |
Pharmacia Corporation |
Crystalline parecoxib sodium
|
US7902257B2
(en)
*
|
2002-04-01 |
2011-03-08 |
University Of Southern California |
Trihydroxy polyunsaturated eicosanoid
|
US8481772B2
(en)
|
2002-04-01 |
2013-07-09 |
University Of Southern California |
Trihydroxy polyunsaturated eicosanoid derivatives
|
JP2005522477A
(ja)
|
2002-04-08 |
2005-07-28 |
グラクソ グループ リミテッド |
(2−((2−アルコキシ)−フェニル)−シクロペント−1−エニル)芳香族炭素環式および複素環式酸および誘導体
|
AU2003226379A1
(en)
*
|
2002-04-18 |
2003-11-03 |
Pharmacia Corporation |
Treatment of parkinson's disease with cyclooxygenase-2 (cox 2) inhibitor(s)
|
JP2005528403A
(ja)
*
|
2002-04-18 |
2005-09-22 |
ファルマシア・コーポレーション |
シクロオキシゲナーゼ−2(cox2)阻害薬によるパーキンソン病処置のための併用療法
|
AU2003229016A1
(en)
*
|
2002-05-10 |
2003-11-11 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
|
AU2003243699B2
(en)
*
|
2002-06-21 |
2009-01-15 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical compositions with improved dissolution
|
CA2488526A1
(en)
*
|
2002-06-26 |
2004-01-08 |
Pharmacia Corporation |
Stable liquid parenteral parecoxib formulation
|
EP1534683A4
(en)
|
2002-06-27 |
2005-08-24 |
Nitromed Inc |
CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHOD OF USE
|
WO2004002420A2
(en)
|
2002-06-28 |
2004-01-08 |
Nitromed, Inc. |
Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
|
EP1536863A1
(en)
*
|
2002-07-02 |
2005-06-08 |
Pharmacia Corporation |
Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event
|
AU2003258194B2
(en)
*
|
2002-08-12 |
2009-11-12 |
The Brigham And Women's Hospital, Inc. |
Resolvins: biotemplates for therapeutic interventions
|
US7759395B2
(en)
|
2002-08-12 |
2010-07-20 |
The Brigham And Women's Hospital, Inc. |
Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
KR100484525B1
(ko)
*
|
2002-10-15 |
2005-04-20 |
씨제이 주식회사 |
이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
US20040082543A1
(en)
*
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
GB0225548D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Compounds
|
US20040092566A1
(en)
*
|
2002-11-12 |
2004-05-13 |
Graneto Matthew J. |
Celecoxib prodrug
|
US20040147581A1
(en)
*
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
US20040127531A1
(en)
*
|
2002-11-21 |
2004-07-01 |
Lu Guang Wei |
Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor
|
US20040126415A1
(en)
*
|
2002-11-21 |
2004-07-01 |
Lu Guang Wei |
Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor
|
US20050020658A1
(en)
*
|
2002-11-21 |
2005-01-27 |
Katsuyuki Inoo |
Selective cyclooxygenase-2 inhibitor patch
|
ATE465725T1
(de)
|
2002-12-13 |
2010-05-15 |
Warner Lambert Co |
Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
|
US20040204411A1
(en)
*
|
2002-12-17 |
2004-10-14 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
US20040235925A1
(en)
*
|
2002-12-17 |
2004-11-25 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
US20080153894A1
(en)
*
|
2002-12-19 |
2008-06-26 |
Pharmacia Corporation |
Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
|
US20040157848A1
(en)
*
|
2002-12-19 |
2004-08-12 |
Pharmacia Corporation |
Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
|
AU2003300264A1
(en)
*
|
2002-12-20 |
2004-07-22 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
|
ES2215474B1
(es)
|
2002-12-24 |
2005-12-16 |
J. URIACH & CIA S.A. |
Nuevos derivados de fosforamida.
|
EP1575566B1
(en)
|
2002-12-26 |
2012-02-22 |
Pozen, Inc. |
Multilayer dosage forms containing naproxen and triptans
|
WO2004060367A1
(en)
*
|
2002-12-30 |
2004-07-22 |
Fujisawa Pharmaceutical Co., Ltd. |
Imidazole and triazole derivatives useful as selective cox-1 inhibitors
|
US8183290B2
(en)
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
US20050026902A1
(en)
*
|
2003-01-31 |
2005-02-03 |
Timothy Maziasz |
Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
|
US20040176378A1
(en)
*
|
2003-02-12 |
2004-09-09 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system
|
WO2004078143A2
(en)
*
|
2003-03-05 |
2004-09-16 |
The Brigham And Women's Hospital Inc. |
Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
|
RU2325189C2
(ru)
*
|
2003-03-20 |
2008-05-27 |
Фармация Корпорейшн |
Способ и фармацевтическая композиция для доставки противовоспалительного средства
|
US20040214753A1
(en)
*
|
2003-03-20 |
2004-10-28 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
US20050004098A1
(en)
*
|
2003-03-20 |
2005-01-06 |
Britten Nancy Jean |
Dispersible formulation of an anti-inflammatory agent
|
US20050009931A1
(en)
*
|
2003-03-20 |
2005-01-13 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
US20040220155A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Pharmacia Corporation |
Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
|
US20040214861A1
(en)
*
|
2003-03-28 |
2004-10-28 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
|
US20050143431A1
(en)
*
|
2003-04-04 |
2005-06-30 |
Hetero Drugs Limited |
Novel crystalline forms of parecoxib sodium
|
WO2004092146A2
(en)
*
|
2003-04-14 |
2004-10-28 |
The Institutes For Pharmaceutical Discovery, Llc |
N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
|
WO2004093895A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
|
US20040220187A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
|
WO2004093816A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
|
US20050009733A1
(en)
*
|
2003-04-22 |
2005-01-13 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
|
US20040224940A1
(en)
*
|
2003-04-22 |
2004-11-11 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage
|
US20060135506A1
(en)
*
|
2003-04-22 |
2006-06-22 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
|
WO2004099168A2
(en)
|
2003-04-30 |
2004-11-18 |
The Institutes For Pharmaceutical Discovery, Llc |
Substituted carboxylic acids
|
US20040220167A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Nasrollah Samiy |
Methods of treating neuralgic pain
|
PL1534305T3
(pl)
|
2003-05-07 |
2007-03-30 |
Osteologix As |
Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
|
US20050107387A1
(en)
*
|
2003-05-13 |
2005-05-19 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
MXPA05012280A
(es)
*
|
2003-05-14 |
2006-02-10 |
Pharmacia Corp |
Composiciones de una bencenosulfonamida o un metilsulfonilbenceno, inhibidores selectivos de ciclooxigenasa-2 y un agente colinergico para el tratamiento de flujo sanguineo reducido o traumatismo en el sistema nervioso central.
|
US20050026919A1
(en)
*
|
2003-05-14 |
2005-02-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
|
US20050159419A1
(en)
*
|
2003-05-14 |
2005-07-21 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
|
WO2004103357A1
(en)
*
|
2003-05-14 |
2004-12-02 |
Pharmacia Corporation |
Compositions for the treatment of reduced blood flow
|
US20050113376A1
(en)
*
|
2003-05-27 |
2005-05-26 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury
|
US20060160776A1
(en)
*
|
2003-05-28 |
2006-07-20 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
|
CN1812983A
(zh)
|
2003-05-30 |
2006-08-02 |
兰贝克赛实验室有限公司 |
取代的吡咯衍生物及其作为hmg-co抑制剂的用途
|
US20050054646A1
(en)
*
|
2003-06-09 |
2005-03-10 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
|
EP1643995A1
(en)
*
|
2003-06-24 |
2006-04-12 |
Pharmacia Corporation |
Treatment of migraine accompanied by nausea
|
US20050080083A1
(en)
*
|
2003-07-10 |
2005-04-14 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage
|
US20050101597A1
(en)
*
|
2003-07-10 |
2005-05-12 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
|
WO2005018541A2
(en)
*
|
2003-07-11 |
2005-03-03 |
Pharmacia Corporation |
Cox-2 inhibitor and serotonin modulator for treating cns damage
|
US20050070543A1
(en)
*
|
2003-07-11 |
2005-03-31 |
Pharmacia Corporation |
Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
|
WO2005009342A2
(en)
*
|
2003-07-16 |
2005-02-03 |
Pharmacia Corporation |
Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
|
US20050075341A1
(en)
*
|
2003-07-17 |
2005-04-07 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
WO2005012268A1
(ja)
*
|
2003-07-30 |
2005-02-10 |
Shionogi & Co., Ltd. |
イソオキサゾール環を有するスルホンアミド誘導体
|
US20070010571A1
(en)
*
|
2003-08-20 |
2007-01-11 |
Nitromed, Inc. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
US20050107350A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Pharmacia Corporation |
Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
|
WO2005018564A2
(en)
*
|
2003-08-22 |
2005-03-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
|
WO2005018563A2
(en)
*
|
2003-08-22 |
2005-03-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
WO2005018569A2
(en)
*
|
2003-08-22 |
2005-03-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia
|
WO2005020910A2
(en)
*
|
2003-08-27 |
2005-03-10 |
Pharmacia Corporation |
Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
CA2536975A1
(en)
*
|
2003-08-28 |
2005-03-17 |
Nitromed, Inc. |
Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
|
US20050113409A1
(en)
*
|
2003-09-03 |
2005-05-26 |
Pharmacia Corporation |
Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
|
US20050113434A1
(en)
*
|
2003-10-03 |
2005-05-26 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury
|
WO2005046615A2
(en)
*
|
2003-11-12 |
2005-05-26 |
Pharmacia & Upjohn Company Llc |
Compositions for treatment of central nervous system mediated disorders
|
BRPI0417197A
(pt)
*
|
2003-12-24 |
2007-03-06 |
Pharmacia Corp |
sais de metais de parecoxib como pró-drogas do inibidor de cox-2 valdecoxib para tratamento de inflamação, dor e/ou febre
|
WO2005079808A1
(en)
|
2004-01-22 |
2005-09-01 |
Pfizer Limited |
Triazole derivatives which inhibit vasopressin antagonistic activity
|
WO2005105025A1
(en)
*
|
2004-04-14 |
2005-11-10 |
Boston University |
Methods and compositions for preventing or treating periodontal diseases
|
BRPI0510340A
(pt)
*
|
2004-04-28 |
2007-10-30 |
Pfizer |
derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
|
CA2571807A1
(en)
|
2004-07-01 |
2006-01-19 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
ES2257929B1
(es)
*
|
2004-07-16 |
2007-05-01 |
Laboratorios Del Dr. Esteve, S.A. |
Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
|
AU2005266088A1
(en)
*
|
2004-07-22 |
2006-02-02 |
Pharmacia Corporation |
Compositions for treatment of inflammation and pain using a combination of a COX-2 selective inhibitor and a LTB4 receptor antagonist
|
WO2006041855A2
(en)
|
2004-10-04 |
2006-04-20 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
WO2006052899A2
(en)
*
|
2004-11-08 |
2006-05-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
|
UY29298A1
(es)
|
2004-12-23 |
2006-05-31 |
Glaxo Group Ltd |
Compuestos
|
AU2006206249A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Nicox S.A. |
Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
|
EP1858525A2
(en)
*
|
2005-02-16 |
2007-11-28 |
Nitromed, Inc. |
Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
|
US7521435B2
(en)
*
|
2005-02-18 |
2009-04-21 |
Pharma Diagnostics, N.V. |
Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
|
AU2006218766A1
(en)
*
|
2005-02-28 |
2006-09-08 |
Nicox S.A. |
Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
NZ562234A
(en)
|
2005-04-26 |
2009-09-25 |
Pfizer |
P-cadherin antibodies
|
US20060251702A1
(en)
*
|
2005-05-05 |
2006-11-09 |
Cook Biotech Incorporated |
Implantable materials and methods for inhibiting tissue adhesion formation
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
EP1885713A1
(en)
*
|
2005-05-18 |
2008-02-13 |
Pfizer Limited |
1, 2, 4 -triazole derivatives as vasopressin antagonists
|
US20090048219A1
(en)
*
|
2005-05-23 |
2009-02-19 |
Nitromed Inc. |
Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
|
HUP0500730A2
(en)
*
|
2005-07-29 |
2007-02-28 |
Richter Gedeon Vegyuszeti Gyar |
1,2-diaryl-heterocyclic compounds, their preparation, pharmaceutical compositions comprising thereof and their use
|
EP1915157A4
(en)
|
2005-08-02 |
2010-09-01 |
Nicox Sa |
NICKEL OXYGENIZING ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND USE PROCESSES
|
TWI387592B
(zh)
*
|
2005-08-30 |
2013-03-01 |
Novartis Ag |
經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
|
RS54393B1
(en)
|
2005-09-07 |
2016-04-28 |
Amgen Fremont Inc. |
HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
|
WO2007041440A2
(en)
|
2005-10-03 |
2007-04-12 |
The Brigham And Women's Hospital, Inc. |
Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
|
CA2624933A1
(en)
*
|
2005-10-04 |
2007-04-12 |
Nitromed, Inc. |
Methods for treating respiratory disorders
|
EP1948599A1
(en)
|
2005-11-08 |
2008-07-30 |
Ranbaxy Laboratories Limited |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
EP1954685A4
(en)
*
|
2005-11-16 |
2009-11-11 |
Nitromed Inc |
FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
|
WO2007061783A1
(en)
*
|
2005-11-18 |
2007-05-31 |
Trustees Of Boston University |
Treatment and prevention of bone loss using resolvins
|
EP1968584A2
(en)
*
|
2005-12-20 |
2008-09-17 |
Nitromed, Inc. |
Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
|
NL2000351C2
(nl)
|
2005-12-22 |
2007-09-11 |
Pfizer Prod Inc |
Estrogeen-modulatoren.
|
EP1971340A2
(en)
*
|
2005-12-22 |
2008-09-24 |
Nitromed, Inc. |
Nitric oxide enhancing pyruvate compounds, compositions and methods of use
|
US20090062302A1
(en)
|
2006-01-24 |
2009-03-05 |
Buser-Doepner Carolyn A |
Jak2 Tyrosine Kinase Inhibition
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US8067414B2
(en)
*
|
2006-03-29 |
2011-11-29 |
Nicox S.A. |
Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
|
KR101464385B1
(ko)
|
2006-04-19 |
2014-11-21 |
노파르티스 아게 |
6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법
|
JP5682051B2
(ja)
|
2006-05-18 |
2015-03-11 |
ファーマサイクリックス,インク. |
細胞内キナーゼ阻害剤
|
WO2008033931A1
(en)
*
|
2006-09-13 |
2008-03-20 |
The Institutes For Pharmaceutical Discovery, Llc |
Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
CN101600458A
(zh)
|
2006-12-22 |
2009-12-09 |
瑞蔻达蒂爱尔兰有限公司 |
采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
|
DK2805945T3
(da)
|
2007-01-10 |
2019-07-15 |
Msd Italia Srl |
Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
|
KR100843351B1
(ko)
*
|
2007-01-30 |
2008-07-03 |
한국과학기술연구원 |
중추신경계 질환 치료제로 유효한n-벤질-n-(2-디메틸아미노-에틸)-벤젠술폰아미드 화합물
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
GB0704407D0
(en)
|
2007-03-07 |
2007-04-18 |
Glaxo Group Ltd |
Compounds
|
MX2009012679A
(es)
|
2007-05-21 |
2009-12-11 |
Novartis Ag |
Inhibidores de csf-1r, composiciones y metodos de uso.
|
EP2170076B1
(en)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
AU2008274941A1
(en)
|
2007-07-12 |
2009-01-15 |
Tragara Pharmaceuticals, Inc. |
Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
|
US7943658B2
(en)
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
KR101257550B1
(ko)
|
2007-09-10 |
2013-04-24 |
칼시메디카, 인크 |
세포내 칼슘을 조절하는 화합물
|
WO2009111354A2
(en)
|
2008-03-03 |
2009-09-11 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
KR101724161B1
(ko)
|
2008-08-27 |
2017-04-06 |
칼시메디카, 인크 |
세포내 칼슘을 조절하는 화합물
|
EP2177215A1
(en)
|
2008-10-17 |
2010-04-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Co-crystals of tramadol and NSAIDs
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
JP5212177B2
(ja)
*
|
2009-02-27 |
2013-06-19 |
東レ株式会社 |
γ−ケトアセタール化合物及びピロール誘導体の製造方法
|
KR101069175B1
(ko)
|
2009-04-19 |
2011-09-30 |
중앙대학교 산학협력단 |
신규 아미노설포닐아릴이소옥사졸계 화합물 및 이를 포함하는 다약제내성 억제용 약제학적 조성물
|
WO2011012622A1
(en)
|
2009-07-30 |
2011-02-03 |
Glaxo Group Limited |
Benzoxazinone derivatives for the treatment of glytl mediated disorders
|
WO2011023753A1
(en)
|
2009-08-27 |
2011-03-03 |
Glaxo Group Limited |
Benzoxazine derivatives as glycine transport inhibitors
|
EP2488028B1
(en)
|
2009-10-14 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
GB201000685D0
(en)
|
2010-01-15 |
2010-03-03 |
Glaxo Group Ltd |
Novel compounds
|
CN101805290A
(zh)
*
|
2010-04-01 |
2010-08-18 |
中国人民解放军第四军医大学 |
氨基磺酰吡唑类化合物及其用途
|
PL2563776T3
(pl)
|
2010-04-27 |
2017-01-31 |
Calcimedica Inc |
Związki, które modulują wewnątrzkomórkowy wapń
|
AU2011248579A1
(en)
|
2010-04-27 |
2012-11-29 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
GB201007791D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel compounds
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
US20130072519A1
(en)
|
2010-05-21 |
2013-03-21 |
Edward Lee Conn |
2-phenyl benzoylamides
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
US9115132B2
(en)
|
2010-07-09 |
2015-08-25 |
Convergence Pharmaceuticals Limited |
Tetrazole compounds as calcium channel blockers
|
EP3330377A1
(en)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
CA2807307C
(en)
|
2010-08-17 |
2021-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
CA2808798C
(en)
*
|
2010-08-20 |
2020-04-28 |
Allergan, Inc. |
Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
AU2011293201B2
(en)
|
2010-08-27 |
2015-11-05 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
ES2541416T3
(es)
|
2011-01-19 |
2015-07-20 |
Convergence Pharmaceuticals Limited |
Derivados de piperazina como bloqueadores de los canales de calcio Cav2.2
|
US20130345392A1
(en)
|
2011-03-04 |
2013-12-26 |
Pfizer Inc |
Edn3-like peptides and uses thereof
|
CN103732592A
(zh)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
胰岛素样生长因子-1受体抑制剂
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2773207B1
(en)
|
2011-10-31 |
2018-03-07 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
EP2780009A4
(en)
*
|
2011-11-17 |
2015-05-06 |
Univ Colorado Regents |
METHODS AND COMPOSITIONS FOR ENHANCED IL-MEDICATION ADMINISTRATION AND EXTENDED DELIVERY FORMULATIONS
|
GB201122113D0
(en)
|
2011-12-22 |
2012-02-01 |
Convergence Pharmaceuticals |
Novel compounds
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
CN105050598B
(zh)
|
2012-09-28 |
2018-04-27 |
默沙东公司 |
作为erk抑制剂的新型化合物
|
WO2014059333A1
(en)
|
2012-10-12 |
2014-04-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
HUE035662T2
(en)
|
2012-11-28 |
2018-05-28 |
Merck Sharp & Dohme |
Compositions and procedures for treating cancer
|
RU2690663C2
(ru)
|
2012-12-20 |
2019-06-05 |
Мерк Шарп И Доум Корп. |
Замещенные имидазопиридины в качестве ингибиторов hdm2
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
NZ712479A
(en)
*
|
2013-03-15 |
2019-01-25 |
Univ Southern California |
Methods, compounds, and compositions for the treatment of angiotensin-related diseases
|
EP3019171B1
(en)
|
2013-07-11 |
2018-09-05 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CN104418818B
(zh)
*
|
2013-09-04 |
2017-01-11 |
天津汉瑞药业有限公司 |
帕瑞昔布钠无水化合物
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CN105085425B
(zh)
*
|
2014-05-23 |
2018-01-30 |
昆药集团股份有限公司 |
一种制备帕瑞昔布的方法
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
GB201417497D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417499D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417500D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
CN104557754A
(zh)
*
|
2015-01-04 |
2015-04-29 |
成都克莱蒙医药科技有限公司 |
一种帕瑞昔布钠杂质的合成方法
|
EP3268367B8
(en)
|
2015-03-12 |
2022-11-16 |
Merck Sharp & Dohme LLC |
Carboxamide inhibitors of irak4 activity
|
EP3267996B1
(en)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
WO2016144849A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
CA2994258A1
(en)
*
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Prodrugs of glutamine analogs
|
US9598361B1
(en)
*
|
2016-04-12 |
2017-03-21 |
King Saud University |
Amino substituted acetamide derivative
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
CN108299331A
(zh)
*
|
2018-03-02 |
2018-07-20 |
成都新恒创药业有限公司 |
一种帕瑞昔布钠光降解杂质及其制备、检测方法和应用
|
CN108164521B
(zh)
*
|
2018-03-02 |
2020-11-13 |
成都新恒创药业有限公司 |
一种帕瑞昔布钠降解杂质及其制备、检测方法和应用
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
CN110305071A
(zh)
*
|
2019-07-23 |
2019-10-08 |
成都通德药业有限公司 |
一种帕瑞昔布钠中间体帕瑞昔布的合成方法
|
JP2023507634A
(ja)
|
2019-12-17 |
2023-02-24 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Prmt5阻害剤
|
IL305573A
(en)
|
2021-03-15 |
2023-10-01 |
Saul Yedgar |
Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases
|
CN115784991A
(zh)
*
|
2022-11-22 |
2023-03-14 |
合肥医工医药股份有限公司 |
N-(苯磺酰基)酰胺衍生物及其制备方法和用途
|